HMCNX
Price
$15.09
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
VMCIX
Price
$71.66
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
Ad is loading...

HMCNX vs VMCIX

Header iconHMCNX vs VMCIX Comparison
Open Charts HMCNX vs VMCIXBanner chart's image
Harbor Mid Cap Investor
Price$15.09
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Mid Cap Index Institutional
Price$71.66
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
HMCNX vs VMCIX Comparison Chart
Loading...
VS
HMCNX vs. VMCIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HMCNX is a StrongBuy and VMCIX is a Buy.

FUNDAMENTALS
Fundamentals
VMCIX has more cash in the bank: 172B vs. HMCNX (167M). VMCIX pays higher dividends than HMCNX: VMCIX (1.50) vs HMCNX (0.12). HMCNX was incepted earlier than VMCIX: HMCNX (5 years) vs VMCIX (26 years). HMCNX is a more actively managed with annual turnover of: 19.00 vs. VMCIX (13.00). HMCNX has a lower initial minimum investment than VMCIX: HMCNX (2500) vs VMCIX (5000000). VMCIX annual gain was more profitable for investors over the last year : 20.58 vs. HMCNX (16.90).
HMCNXVMCIXHMCNX / VMCIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years26 years-
Gain YTD8.55311.33675%
Front LoadN/AN/A-
Min. Initial Investment250050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets167M172B0%
Annual Yield % from dividends0.121.508%
Returns for 1 year16.9020.5882%
Returns for 3 years6.246.8092%
Returns for 5 yearsN/A55.18-
Returns for 10 yearsN/A122.16-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NRGV1.000.03
+2.76%
Energy Vault Holdings
ELVN21.760.29
+1.35%
Enliven Therapeutics
HIG116.70-0.37
-0.32%
Hartford Financial Services Group (The)
FOUR83.58-0.36
-0.43%
Shift4 Payments
CUE0.55-0.02
-2.86%
Cue Biopharma